ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Osteoarthritis"

  • Abstract Number: 977 • 2014 ACR/ARHP Annual Meeting

    Randomized Clinical Trial of a Patient and Provider Intervention for Managing Osteoarthritis in Veterans

    Kelli D. Allen1,2, Hayden B. Bosworth3,4, Amy Jeffreys1, Cynthia Coffman3,5, Santanu Datta4,6, Jennifer McDuffie1,7, Eugene Oddone3,4, Jennifer Strauss1,8 and William S. Yancy Jr.1,4, 1Health Services Research, Durham VA Medical Center, Durham, NC, 2Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Health Services Research, Durham VA Medical Center and Duke University Medical Center, Durham, NC, 4Department of Medicine, Division of General Internal Medicine, Duke University Medical Center, Durham, NC, 5Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, 6Health Services Reserach, Durham VA Medical Center and Duke University Medical Center, Durham, NC, 7Medicine, Duke University Medical Center, Durham, NC, 8Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC

    Background/Purpose: Adequate management of osteoarthritis (OA) requires both medical and behavioral strategies. However, some recommended therapies are under-utilized in clinical settings, and there is low…
  • Abstract Number: 2337 • 2014 ACR/ARHP Annual Meeting

    The Cost and Effectiveness of Various Recruitment Strategies in a Mind Body Clinical Trial Among Older Adults with Knee Osteoarthritis

    Jade V. Goldsmith1, Lori Lyn Price2, Jeffrey B. Driban3, William F. Harvey3 and Chenchen Wang3, 1Center for Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, 2Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, 3Rheumatology, Tufts Medical Center, Boston, MA

    Background/Purpose : Recruitment and adherence are important and challenging factors that can determine the success of a clinical trial. Mind body therapies are an emerging and…
  • Abstract Number: 978 • 2014 ACR/ARHP Annual Meeting

    Socioeconomic Status Measures Are Associated with Increasing Pain, Stiffness and Physical Function Among Individuals with Knee and Hip Osteoarthritis

    Rebecca J. Cleveland1, Jordan B. Renner2, Joanne M. Jordan3 and Leigh F. Callahan4, 1Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina Department of Radiology, Chapel Hill, NC, 3University of North Carolina Dept of Epidemiology, Chapel Hill, NC, 4Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC

    Background/Purpose The determinants of disability progression (DP) among those with knee and/or hip osteoarthritis (OA) are not well known. Our aim was to explore whether…
  • Abstract Number: 2233 • 2014 ACR/ARHP Annual Meeting

    A PHASE 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy Study of Apremilast (CC-10004) in Subjects with Erosive Hand Osteoarthritis

    Juergen Rech1, Francesca Faustini1, Axel J. Hueber1, Wolfgang Ochs2, Wolfgang Spieler3, Herbert Kellner4, Ulf Muller-Ladner5, Mathias Grünke6, Matthias Schneider7 and Georg Schett8, 1Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 2Rheumatologist in private practice, Bayreuth, Germany, 3Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, 4Centre for Inflammatory Joint Diseases, Munich, Germany, 5Internal Medicine/Rheumatology, Univ Giessen/Kerckhoff-Clinic, Bad Nauheim, Germany, 6Division of Rheumatology, University of Munich, Munich, Germany, 7Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, 8Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose We report on a phase II, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study in subjects with erosive hand osteoarthritis. Subjects must have had…
  • Abstract Number: 922 • 2014 ACR/ARHP Annual Meeting

    A Potential Role for TLR4 Activation in Osteoarthritis Associated Pain

    Rachel E. Miller1, Shingo Ishihara2, Phuong Tran3, Richard J. Miller4 and Anne-Marie Malfait5, 1Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, 2Internal Medicine, Rush University Medical Center, Chicago, IL, 3Rheumatology, Rush University Medical Center, Chicago, IL, 4Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, 5Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL

    Background/Purpose - Damage associated molecular patterns (DAMPs) result from cellular stress and extracellular matrix breakdown. They may contribute to osteoarthritis (OA) pathogenesis by promoting synovitis…
  • Abstract Number: 2237 • 2014 ACR/ARHP Annual Meeting

    Interleukin-1 Dual-Variable Domain Immunoglobulin Reduces Multiple Inflammatory Markers in Knee Osteoarthritis Patients

    Susanne X. Wang1, Jeroen Medema1, Matthew Kosloski1, Wei Liu1, Mary Saltarelli1 and Morten Asser Karsdal2, 1AbbVie Inc., North Chicago, IL, 2Nordic Bioscience, Biomarkers and Research, Herlev, Denmark

    Background/Purpose: Osteoarthritis (OA) may comprise multiple phenotypes, one of which is inflammation-driven OA. Consequently, a selected subpopulation of OA patients may benefit from optimally targeted…
  • Abstract Number: 257 • 2014 ACR/ARHP Annual Meeting

    Quality of Life Assessment of Adults Patients with X-Linked Hypophosphoremia

    Karine Briot1, Hélène Ché1, Adrien Etcheto1, Anya Rothenbuhler2, Peter Kamenicky,2, Agnès Linglart2 and Christian Roux3, 1Cochin Hospital, Paris Descartes University, Paris, France, 2Hôpital Bicêtre, Kremlin Bicêtre, France, 3Paris Descartes University, Cochin Hospital, Paris, France

    Background/Purpose: X-Linked Hypophosphatemia (XLH) is the most common form of heritable rickets. Although disease severity is variable, adults with XLH may suffer from skeletal symptoms…
  • Abstract Number: 2243 • 2014 ACR/ARHP Annual Meeting

    Comparison Between Two Diclofenac Diethylamine Gel Formulations, 1.16% Vs 2.32%: Is It Only Increasing the Strength of the Active Ingredient Enough?

    Giuseppa Quartarone1 and Nathalie Hasler-Nguyen2, 1Medical Affairs, Novartis CH R&D OU Italy Greece, Milan, Italy, 2Pre-Cinical Development, Novartis CH Global R&D, Nyon, Switzerland

    Background/Purpose Topically applied non-steroidal anti-inflammatory drugs (NSAIDs) can produce clinically effective drug concentrations at a peripheral site, but with low systemic concentrations and thus a…
  • Abstract Number: 249 • 2014 ACR/ARHP Annual Meeting

    A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes

    Vibeke Strand1, Allan Gibofsky2, Marc Hochberg3, Roy Altman4, Byron Cryer5, Alan Kivitz6, Olaolu Imasogie7 and Clarence Young8, 1Stanford University, Palo Alto, CA, 2Medicine and Public Health, Hospital for Special Surgery, New York, NY, 3University of Maryland School of Medicine, College Park, MD, 4University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5University of Texas Southwestern Medical Center, Dallas, TX, 6Altoona Center for Clinical Research, Duncansville, PA, 7Iroko Pharmaceuticals LLC, Philadelphia, PA, 8150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA

    Background/Purpose: Diclofenac is used for the treatment of osteoarthritis (OA), but, like other NSAIDs, it is associated with serious dose-related adverse events. The FDA has…
  • Abstract Number: 2247 • 2014 ACR/ARHP Annual Meeting

    Bariatric Surgery Improves Quality of Life in Patients with Osteoarthritis and Obesity Compared to Non-Surgical Weight Loss

    Christopher Chong1, Sangeeta Kashyap2, Philip Schauer2, Colin O'Rourke3 and M. Elaine Husni4, 1Rheumatology, Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH, 3Quantitative Health Sciences, JJN3-01, Cleveland Clinic, Cleveland, OH, 4Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Numerous studies support obesity as a strong risk factor for development and progression of knee osteoarthritis (OA).  The potential benefits of massive weight loss,…
  • Abstract Number: 222 • 2014 ACR/ARHP Annual Meeting

    OA Phenotypes Rather Than Disease Stage Drive Structural Progression – Identification of Structural Progressors from 2 Phase III Randomized Clinical studies with Symptomatic Knee OA

    Morten Asser Karsdal1, Anne C. Bay-Jensen2, Asger Bihlet3, Peter Alexandersen4, Inger Byrjalsen3, Bente J. Riis3 and Claus Christiansen3, 1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Nordic Bioscience, Herlev, Denmark, 4Center for Clinical and Basic Research, Vejle, Denmark

    Background/Purpose: Osteoarthritis (OA) is a heterogeneous disorder, with several possible drivers of disease progression. Up to 50% of OA patients do not structurally progress, emphasizing…
  • Abstract Number: 2141 • 2014 ACR/ARHP Annual Meeting

    Sensitivity to Change of Joint Space Width Measurements in Hand Osteoarthritis in a Two Year Follow-up Study

    W. Damman1, S.E. de Bruin1, B.C. Stoel2, R. van 't Klooster2 and M. Kloppenburg1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Radiology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Cartilage loss, represented by joint space width (JSW) on radiographs, is an important outcome measure in hand OA disease course. JSW can be assessed…
  • Abstract Number: 219 • 2014 ACR/ARHP Annual Meeting

    DXA Body Composition, Sarcopenia and Knee and Hip Osteoarthritis: Results from the Khoala Cohort

    Clémence Jeanmaire1, Isabelle Chary-Valkenaere1, Damien Loeuille2, Lorraine Bernard3 and Anne-Christine Rat,4, 1Rheumatology, CHU Nancy, Vandoeuvre Les Nancy, France, 2Rheumatology, CHU Brabois, Vandoeuvre les Nancy, France, 3CHU Nancy, Pôle S2R, Epidémiologie et Evaluation Cliniques, INSERM, CIC-EC, CIE6, Vandoeuvre Les Nancy, France, 4Université de Lorraine, Nancy, F-54000, France; Inserm, , CIC-EC, CIC 1433, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France

    Background/Purpose Obesity is a well known risk factor for the development and progression of knee osteoarthritis (OA), and to a lesser extent of hip OA.…
  • Abstract Number: 2913 • 2013 ACR/ARHP Annual Meeting

    The Validity Of Patient-Reported Short-Term Complications Following Total Hip and Knee Arthroplast

    Leslie R. Harrold1, David Ayers2, Regis O'Keefe3, Courtland Lewis4, Vincent Pellegrini5 and Patricia D. Franklin2, 1University of Massachusetts Medical School, Worcester, MA, 2Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, 3University of Rochester Medical Center, Rochester, NY, 4Hartford Hospital, Hartford, CT, 5Medical University of South Carolina, Charleston, SC

    Background/Purpose: Given the absence of national longitudinal data on patients who undergo total joint arthroplasty (TJA) and the limitations of hospital databases to capture information…
  • Abstract Number: 1887 • 2013 ACR/ARHP Annual Meeting

    Interleukin-1 Receptor Antagonist (IL-1Ra) Plasma Levels Predict Radiographic Progression Of Symptomatic Knee Osteoarthritis Over 24 Months

    Mukundan Attur1, Alexander Statnikov2,3, Jonathan Samuels4, Svetlana Krasnokutsky1, Jeffrey D. Greenberg1, Zhiguo Li2, Leon Rybak5, Constantin F. Aliferis2,6 and Steven B. Abramson7, 1Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, 2Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, NY, 3Division of Translational Medicine, NYU Langone Medical Center, New York, NY, 4Division of Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY, 5Department of Radiology, NYU Langone Medical Center, New York, NY, 6Department of Pathology, NYU Langone Medical Center, New York, NY, 7Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY

    Background/Purpose: Osteoarthritis is multi-factorial complex degenerative joint disease that leads to permanent joint damage. We and others have shown elevated levels of inflammatory and anti-inflammatory…
  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 71
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology